TSLP and asthma: Tezepelumab binds to TSLP, preventing its interaction with its receptor complex predominantly on dendritic cells impairing the downstream activation of signaling pathways such as signal transducer and activator of transcription-3 (STAT3) and Janus kinase-1 (JAK1) that are also involved in T2-low asthma (Menzies-Gow et al., 2021; Corren et al., 2023).